DUBLIN, Ireland – Trino Therapeutics Ltd., a spinout from Trinity College Dublin (TCD), raised €9 million (US$11.6 million) in a Series A round to move PH46A, an oral, first-in-class indane dimer, into clinical trials in ulcerative colitis.